FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2506306922> ?p ?o ?g. }

• W2506306922 endingPage "896" @default.
• W2506306922 startingPage "896" @default.
• W2506306922 abstract "Galectins are a family of endogenous β glycan-binding proteins that play an important role in the modulation of inflammation-associated with neurodegeneration as seen in various neurological disorders such as dementia, multiple sclerosis (MS), Alzheimer's disease (AD) (Chen et al., 2014). Members of the galectin family specifically galectin-1, -3 and -9 are involved in neuromodulation via cytokine production contributing to central nervous system (CNS) pathology and/or neuro-preservation. Galectins are expressed by activated microglia/infiltrating macrophages and astrocytes and recently we have shown that they are also expressed by brain microvascular endothelial cells that constitute the blood-brain barrier (BBB) (Parikh et al., 2015). Several studies have shown that galectins are important modulators participating in homeostasis of the CNS and neuroinflammation. Galectins contribute to CNS pathophysiology by either controlling the inflammatory response or by remodeling damaged CNS tissues. Since galectins are pro-inflammatory mediators in the CNS, either modulation of their expression or activity could be a sound therapeutic strategy for a variety of neurological disorders mentioned above.HIV-1 targets the CNS early in infection, specifically in subcortical brain regions resulting in cognitive disturbances linked both to viral activity and inflammatory response leading to the neuronal apoptosis causing a spectrum of HIV-associated neurocognitive disorders (HAND). Long-term HIV replication in the brain occurs in astrocytes and microglia, allowing the sequestered virus to compromise neuronal function. Galectin-1 promotes HIV-1 binding to susceptible CD4+ cells enhancing viral infection suggesting that CD4 is one of the host ligand of galectin-1 (Mercier et al., 2008; St-Pierre et al., 2011). It is believed that galectin-1 facilitates HIV-1 infection through direct cross-linking of HIV gp120 and host cell surface CD4 receptor. Additionally, galectin-1 promotes infection of HIV-1 X4, X4R5, and R5 variants in susceptible cells as well. HIV-1 susceptible CNS cells may have affinity for galectin-1 due to the presence of glycosylated protein receptors thus responding to the immunomodulatory effects mediated by galectin-1. Microglial cells are the resident macrophages of the brain and act as the first line of defense in the CNS microglia constitute the lesser portion of the total glial cell population within the brain and are found in a resting state in the healthy CNS. Under pathological conditions microglia get activated and undergo morphological changes in addition to inducing expression of proinflammatory cytokines like interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor-α (TNF-α), chemokines, reactive oxygen and nitrogen species, all of which cause neuronal damage (Kettenmann et al., 2011). A variety of microglia receptors are involved in triggering an inflammatory response, specifically via receptor for advanced glycosylation endproducts (RAGE), complement receptor C5aR and certain toll like receptors (TLRs). C5a is a highly proinflammatory molecule generated in the process of complement activation. CD88 is a receptor for C5a expressed on the surface of innate immune cells, including microglia. The interaction between C5a and CD88 leads to the production of inflammatory cytokines and reactive oxygen species. (Woodruff et al., 2010). Microglial expression of TLR-2, -4 and -9, have been associated with microglial activation and neurotoxicity highlighting their role in neuropathology (Lehnardt, 2010). It will be interesting to investigate if galectin-1 modulates the expression of RAGE, C5aR or TLRs thereby altering inflammatory response. Our current studies are focused on exploring these mechanisms of galectin-1 action.In the context of HAND, activation of TLRs on microglial cells by morphine and HIV protein TAT has been shown to contribute to the increased neuropathophysiology (Dutta et al., 2012). HIV-1 Tat or gp120 alone and in combination with morphine modulate the expression of TLR-2, -4 in astrocytes resulting in the release of inflammatory cytokines (El-hage et al., 2011). Although the role of these microglial receptors in the neuroinflammatory response is established, limited information is available on the role of endogenous ligands such as galectins that may trigger activation of TLRs, C5aR or RAGE. A recent report showed galectin-3-dependent-TLR4 activation could contribute to sustained microglia activation, prolonging the inflammatory response in the brain (Burguillos et al., 2015).Activated microglia contribute to CNS pathology or repair, depending on the prevalent microenvironment and their mode of activation, typically activated microglia are associated with neurodegeneration. When endogenous galectin-1 is absent, classical microglial activation occurs, concurrent with an increase in demyelination, axonal loss and a reduction in endogenous synaptic repair. Within CNS inflamed tissues, Iba1+ cells are represented by microglia and when galectin-1 is present, there is a downregulation of activation markers, proinflammatory cytokines, and inducible nitric oxide synthase (iNOS) expression.The underlying mechanisms of galectin-1 mediated neuroprotection occur by inactivation of microglia, via the establishment of galectin-1-N-linked glycan interactions on microglial cells that may provide an endogenous mechanism to limit neuropathology. Galectin-1-N-linked-glycan interactions can adjust thresholds of cellular activation and survival through modulation of endocytosis, trafficking, and signaling of canonical receptors (Starossom et al., 2012). Therefore, targeting the galectin1-N-linked glycan interactions will result in decrease of inflammation-associated neurodegeneration and may represent a new therapeutic approach for neurodegenerative diseases like HIV-1 dementia.Our research is focused on evaluating mechanism(s) that contribute to neuroinflammation and neurodegeneration in HIV-1 infection in the context of drug abuse and we have shown that galectin-1 is neuroprotective (Reynolds et al., 2012; Parikh et al., 2015). We are currently examining the effect of galectin-1 treatment on inflammatory response and cellular apoptosis in vitro in normal and HIV infected primary human microglia. For these studies we use primary human microglial cells CHME-5 and HIV-latently infected CHME-5 cells (generously donated by Dr. J. Karn, CWRU, Cleveland, OH). CHME-5 cell line was created by transfecting human fetal microglia with the large T antigen of the simian virus 40 and both CHME-5/CHME-5 HIV microglia are maintained in Dulbecco's minimal essential medium, high glucose (DMEM HG) supplemented with 5% FBS and 1% penicillin/streptomycin. Treatment of CHME-5 and CHME-5/HIV with LPS (50 ng/mL) stimulated the release of proinflammatory cytokines resulting in an increase in oxidative stress as measured by reactive oxygen species (ROS) production. ROS includes superoxide (O2), hydrogen peroxide (H2O2) and hydroxyl radical (OH), which under physiological conditions are generated at low levels and play important roles in signaling and metabolic pathways. Increased oxidative stress causes the generation of ROS, which are potentially toxic for cells further contributing to neuroinflammation. We observed increased Iba1+ expression in HIV transfected CHME-5/HIV microglia as compared to untransfected CHME-5 cells indicative of increased microglial activation in HIV infected cells (Figure ​Figure1A,1A, ​,BB). We hypothesize that galectin-1 will reduce neuroinflammation in both human microglia cell line CHME-5 and CHME-5/HIV. Our results (Figure ​Figure1C,1C, ​,DD) showed that treatment with galectin-1 (1 µM) decreased microglial activation in both CHME-5 and CHME-5/HIV cells. Histograms shown in Figure ​Figure1E,1E, ​,FF show the Image J quantitation of fluorescence signal intensity in pixel units of representative fluorescent images shown in Figure ​Figure1A,1A, ​,BB and Figure ​Figure1C,1C, ​,DD respectively. Treatment of microglia with pro-inflammatory cytokines LPS resulted in a 60% increase (P < 0.01) in oxidative stress in CHME-5 and a 26% increase (P < 0.05) in CHME5/HIV respectively compared to the untreated controls. Further, treatment of microglia with galectin-1 (1 µM) reduced oxidative stress by ~25% (P < 0.05) in CHME5 by ~60% (P < 0.01) in CHME-5/HIV when compared to the LPS treated cells (Figure 2). Our data suggests that galectin-1 treatment could reduce neuroinflammation via decreased oxidative stress and we propose that mechanism such as the nitric oxide-arginase network may potentially play a neuroprotective role in HAND. Our current research is focused on further exploring the mechanism by which galectin-1 mediates CNS homeostasis.Figure 1Immunofluorescence staining using Iba-1 antibody.Figure 2ROS/RNS assay (Cell Biolabs kit).Currently, a galectin-1 inhibitor (OTX008) is undergoing phase I clinical trials and is believed to have potential anti-angiogenic and antineoplastic activities. A galectin-3 inhibitor GR-MD-02 is also in early phase I clinical trials, is shown to be safe and well tolerated, in patients with fatty liver disease/nonalcoholic steatohepatitis (NASH) and advanced liver fibrosis. In light of the neuroprotective properties of galectin-1, its targeted overexpression would be a novel therapeutic approach for several neurodegenerative pathologies." @default.
• W2506306922 created "2016-08-23" @default.
• W2506306922 creator A5052017501 @default.
• W2506306922 creator A5072872357 @default.
• W2506306922 date "2016-01-01" @default.
• W2506306922 modified "2023-10-14" @default.
• W2506306922 title "Neuroprotective role of galectin-1 in central nervous system pathophysiology" @default.
• W2506306922 cites W1073627852 @default.
• W2506306922 cites W12332796 @default.
• W2506306922 cites W1971102239 @default.
• W2506306922 cites W1978655989 @default.
• W2506306922 cites W1998892759 @default.
• W2506306922 cites W2007653463 @default.
• W2506306922 cites W2067267561 @default.
• W2506306922 cites W2080432978 @default.
• W2506306922 cites W2085662515 @default.
• W2506306922 cites W2096319352 @default.
• W2506306922 cites W2103643424 @default.
• W2506306922 cites W2133030190 @default.
• W2506306922 doi "https://doi.org/10.4103/1673-5374.184455" @default.
• W2506306922 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4962575" @default.
• W2506306922 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27482206" @default.
• W2506306922 hasPublicationYear "2016" @default.
• W2506306922 type Work @default.
• W2506306922 sameAs 2506306922 @default.
• W2506306922 citedByCount "11" @default.
• W2506306922 countsByYear W25063069222016 @default.
• W2506306922 countsByYear W25063069222021 @default.
• W2506306922 countsByYear W25063069222022 @default.
• W2506306922 countsByYear W25063069222023 @default.
• W2506306922 crossrefType "journal-article" @default.
• W2506306922 hasAuthorship W2506306922A5052017501 @default.
• W2506306922 hasAuthorship W2506306922A5072872357 @default.
• W2506306922 hasBestOaLocation W25063069221 @default.
• W2506306922 hasConcept C10162356 @default.
• W2506306922 hasConcept C142724271 @default.
• W2506306922 hasConcept C169760540 @default.
• W2506306922 hasConcept C25498285 @default.
• W2506306922 hasConcept C529278444 @default.
• W2506306922 hasConcept C60644358 @default.
• W2506306922 hasConcept C71924100 @default.
• W2506306922 hasConcept C86803240 @default.
• W2506306922 hasConceptScore W2506306922C10162356 @default.
• W2506306922 hasConceptScore W2506306922C142724271 @default.
• W2506306922 hasConceptScore W2506306922C169760540 @default.
• W2506306922 hasConceptScore W2506306922C25498285 @default.
• W2506306922 hasConceptScore W2506306922C529278444 @default.
• W2506306922 hasConceptScore W2506306922C60644358 @default.
• W2506306922 hasConceptScore W2506306922C71924100 @default.
• W2506306922 hasConceptScore W2506306922C86803240 @default.
• W2506306922 hasIssue "6" @default.
• W2506306922 hasLocation W25063069221 @default.
• W2506306922 hasLocation W25063069222 @default.
• W2506306922 hasLocation W25063069223 @default.
• W2506306922 hasLocation W25063069224 @default.
• W2506306922 hasLocation W25063069225 @default.
• W2506306922 hasOpenAccess W2506306922 @default.
• W2506306922 hasPrimaryLocation W25063069221 @default.
• W2506306922 hasRelatedWork W2050697792 @default.
• W2506306922 hasRelatedWork W2067467642 @default.
• W2506306922 hasRelatedWork W2077302930 @default.
• W2506306922 hasRelatedWork W2084272464 @default.
• W2506306922 hasRelatedWork W2157625858 @default.
• W2506306922 hasRelatedWork W2747715884 @default.
• W2506306922 hasRelatedWork W2965035470 @default.
• W2506306922 hasRelatedWork W3030373829 @default.
• W2506306922 hasRelatedWork W3143637439 @default.
• W2506306922 hasRelatedWork W70727126 @default.
• W2506306922 hasVolume "11" @default.
• W2506306922 isParatext "false" @default.
• W2506306922 isRetracted "false" @default.
• W2506306922 magId "2506306922" @default.
• W2506306922 workType "article" @default.